Envoy Medical (COCH) Projected to Release Quarterly Earnings on Thursday

Envoy Medical (NASDAQ:COCH) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.70) per share and revenue of $0.09 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Envoy Medical (NASDAQ:COCH) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.10. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. On average, analysts expect Envoy Medical to post ($3.10) EPS for the current fiscal year and ($1.80) EPS for the next fiscal year.

Envoy Medical Trading Up 2.3%

Shares of Envoy Medical stock opened at $6.66 on Thursday. Envoy Medical has a 1 year low of $3.63 and a 1 year high of $9.54. The company has a market cap of $514.09 million, a P/E ratio of -0.88 and a beta of 1.97. The stock has a 50-day moving average price of $6.90 and a 200 day moving average price of $6.87.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on COCH. Weiss Ratings reissued a “sell (e+)” rating on shares of Envoy Medical in a research report on Monday, October 19th. HC Wainwright reaffirmed a “buy” rating on shares of Envoy Medical in a research report on Tuesday, October 13th. Lake Street Capital upped their price objective on shares of Envoy Medical from $2.50 to $25.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Loop Capital set a $20.00 price target on shares of Envoy Medical in a report on Monday, July 27th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $21.67.

Envoy Medical Company Profile

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.